Turn Therapeutics Inc. TTRX
9.04 USD -0.76 (-7.76%)
Nov 5, 2026, 1:33 PM EST
8.56 Day range 10.19
2.57 52-week range 16.45
- YTD
- +129.44%
- 1 year
- +109.26%
- Market cap
- 273.31M
- EPS (ttm)
- -0.29
- YTD return
- +129.44%
- 1-year return
- +109.26%
- Volume
- 42.96K
- Avg volume
- 110.19K
- Open
- 10.19
- Previous close
- 9.80
- Day's range
- 8.56 – 10.19
- 52-week range
- 2.57 – 16.45
2Y +2.00 (+28.57%)
Financials — quick view
TTRX Revenue — quarterly 0
TTRX Net income — quarterly -5.85M
TTRX EPS — quarterly -0.20
News
Turn Therapeutics' GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program 
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday 
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday 
WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10 
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat 
This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24
WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target 
12 Health Care Stocks Moving In Friday's After-Market Session 
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
Your note
Sign in to keep a note on TTRX — it syncs with the Stock Master app.